Latest news with #EgyptianDrugAuthority
Egypt Today
05-03-2025
- Health
- Egypt Today
Egypt, Armenia talk enhancing cooperation in health sector
Egyptian Deputy Prime Minister and Minister of Health and Population Khaled Abdel Ghaffar CAIRO - 5 March 2025: Egyptian Deputy Prime Minister and Minister of Health and Population Khaled Abdel Ghaffar had a meeting on Wednesday with Armenian Ambassador in Cairo Armen Sargsyan and his accompanying delegation to discuss boosting cooperation in the pharmaceutical manufacturing domain. During the meeting, the two sides discussed re-activating the agreements signed by the two countries' health ministries, along with exchanging medical expertise. Regarding the medicines and vaccines sector, the two parties discussed the possibility of exporting Egyptian medicines to Armenia, and concluding bilateral agreements in this regard. Also, an invitation was extended to the Armenian side to visit the Egyptian Drug Authority (EDA) to stand on procedures for registering and exporting pharmaceuticals, particularly through "VACSERA" company. The two sides also discussed arranging a visit for a group of Egyptian drug manufacturers and health workers to Armenia in July, with the view to exploring opportunities for cooperation between companies and medical centers in the two countries, and beefing up joint healthcare and pharma investments. For his part, the Armenian diplomat said he looks forward to benefiting from the Egyptian expertise in the fields of manufacturing and localizing medicines, providing medical training, and exchanging medical expertise. Amb. Sargsyan also extended an official invitation to the Egyptian health minister to visit Armenia with the view to promoting bilateral cooperation in the health sector.
Zawya
10-02-2025
- Health
- Zawya
Servier Egypt celebrates jubilee with new production line, cancer programme
Egypt - Servier Egypt, part of the global Servier Group, has commemorated its 70th anniversary with the opening of a new production line and the launch of the 'Access Cancer Treatment (ACT) for Children' initiative. The announcements were made at an event attended by Ali El Ghamrawy, Head of the Egyptian Drug Authority, and Hesham Stait, Head of the Egyptian Authority for Unified Procurement. Stait highlighted the importance of public-private partnerships for Egypt's Vision 2030. Servier Egypt has been operating in the country for over 50 years, focusing on sustainable development and access to treatments. It currently produces 25 million boxes of medication annually for Egyptian patients. The company's pharmaceutical site in 6th of October City, one of Servier Group's eight worldwide, was established in 1994. Production has grown to 25 million boxes annually, with 90% for the local market and 10% exported to nine countries in Africa and the Middle East. Servier has invested over EGP 1.6 billion in its Egyptian operations, including EGP 370 million in 11 projects focused on capacity building, corporate social responsibility, and digital procedures. These include solar panels, a wastewater treatment system, and a new packaging line. The company aims to produce 50 million boxes annually by 2030, increasing exports and partnerships to position Egypt as a regional pharmaceutical hub. 'This milestone reaffirms our long-standing commitment to Egypt's Vision 2030,' said Samy Sinnuqrut, General Manager of Servier Egypt. 'By investing in local production and innovation, we aim to enhance patient access to advanced treatments while contributing to Egypt's economic and healthcare priorities.' Servier Egypt offers 34 medicines, including treatments for cardio-metabolism, venous diseases, and oncology, with plans to introduce two more oncology treatments. The ACT for Children initiative, in partnership with other organisations, addresses childhood cancer disparities. 'Through ACT for Children, we aim to create long-term infrastructure and sustainable healthcare solutions that ensure children everywhere have access to the care and treatments they need,' Sinnuqrut said. 'This is central to our Servier 2030 ambition to make a measurable, positive social impact.' Servier Egypt offers 32 solid dosage form products, along with two specialised oncology medications. © 2024 Daily News Egypt. Provided by SyndiGate Media Inc. (
Daily News Egypt
10-02-2025
- Health
- Daily News Egypt
Servier Egypt celebrates jubilee with new production line, cancer programme
Servier Egypt, part of the global Servier Group, has commemorated its 70th anniversary with the opening of a new production line and the launch of the 'Access Cancer Treatment (ACT) for Children' initiative. The announcements were made at an event attended by Ali El Ghamrawy, Head of the Egyptian Drug Authority, and Hesham Stait, Head of the Egyptian Authority for Unified Procurement. Stait highlighted the importance of public-private partnerships for Egypt's Vision 2030. Servier Egypt has been operating in the country for over 50 years, focusing on sustainable development and access to treatments. It currently produces 25 million boxes of medication annually for Egyptian patients. The company's pharmaceutical site in 6th of October City, one of Servier Group's eight worldwide, was established in 1994. Production has grown to 25 million boxes annually, with 90% for the local market and 10% exported to nine countries in Africa and the Middle East. Servier has invested over EGP 1.6 billion in its Egyptian operations, including EGP 370 million in 11 projects focused on capacity building, corporate social responsibility, and digital procedures. These include solar panels, a wastewater treatment system, and a new packaging line. The company aims to produce 50 million boxes annually by 2030, increasing exports and partnerships to position Egypt as a regional pharmaceutical hub. 'This milestone reaffirms our long-standing commitment to Egypt's Vision 2030,' said Samy Sinnuqrut, General Manager of Servier Egypt. 'By investing in local production and innovation, we aim to enhance patient access to advanced treatments while contributing to Egypt's economic and healthcare priorities.' Servier Egypt offers 34 medicines, including treatments for cardio-metabolism, venous diseases, and oncology, with plans to introduce two more oncology treatments. The ACT for Children initiative, in partnership with other organisations, addresses childhood cancer disparities. 'Through ACT for Children, we aim to create long-term infrastructure and sustainable healthcare solutions that ensure children everywhere have access to the care and treatments they need,' Sinnuqrut said. 'This is central to our Servier 2030 ambition to make a measurable, positive social impact.' Servier Egypt offers 32 solid dosage form products, along with two specialised oncology medications.
Zawya
31-01-2025
- Business
- Zawya
UAE-based EVOTEQ to expand in MENA, beyond through partnership with Egypt's DAF
Mubasher: EVOTEQ, a Dubai-based solutions provider, has partnered with Digital Access to Finance (DAF), the Egyptian company managing the implementation and operation of the Egyptian Drug Authority's (EDA) national track-and-trace system. This collaboration will bring a cutting-edge solution to Egypt, marking a pivotal step toward redefining medicine traceability, enhancing patient safety, combating counterfeit drugs and managing potential drug shortages, according to a press release. Founder and Managing Director of DAF, Hatem Kandeel, said: 'This partnership reflects our commitment to adopting world-class innovations that safeguard patient health and strengthen Egypt's healthcare ecosystem.' Kandeel noted: 'Once we have launched in Egypt, I envision that DAF and EVOTEQ will expand to MENA region and Africa as the established service providers in the pharmaceutical regulation domain.' He added: 'Integrating cutting edge solutions within our systems in collaboration with EVOTEQ ensures that every step of the healthcare supply chain is secure, efficient, transparent and will add value to the pharma-manufacturing field in Egypt.' The partnership was formalised through signing of a memorandum of understanding (MOU) in the presence of the CEO of the Egyptian Company for Medical Investment, Ahmed Afifi, on the third day of Arab Health 2025 at the Dubai World Trade Center. It strategically builds on EVOTEQ's proven success in revolutionizing healthcare traceability in the UAE. CEO of EVOTEQ, Jihad Tayara, said: 'Our collaboration with DAF Egypt is more than a partnership; it's a shared mission to elevate healthcare standards and protect lives.' Tayara noted: 'By extending our joint capabilities to Egypt, we are addressing critical challenges in medicine authentication and laying the foundation for a future where trust and transparency are at the core of every healthcare system.' The partnership is established to serve Egypt's healthcare framework will empower the Egyptian Drug Authority to monitor and validate medicines with unmatched precision, building on the successes already achieved by EVOTEQ in the UAE in combating counterfeit medicines, optimizing supply chains, and ensuring patients receive safe, authentic treatments for their wellbeing and safety. Additionally, this MoU is a bold step toward a more innovative and safer healthcare ecosystem across the MENA region and Africa. By combining EVOTEQ's expertise in secure supply chain solutions with DAF Egypt's leadership in regulatory systems, this partnership is poised to redefine global standards in medicine traceability and patient care.
